These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.
    Author: Chirgwin J, Chua SL.
    Journal: Breast; 2011 Oct; 20(5):394-406. PubMed ID: 21839635.
    Abstract:
    BACKGROUND: Monotherapy with nanoparticle albumin-bound (nab)-paclitaxel has demonstrated improved efficacy and safety compared with solvent-based paclitaxel and docetaxel. DESIGN: A comprehensive review of all reported studies of nab-paclitaxel combinations with other agents in all breast cancer settings was undertaken. RESULTS: Most studies reviewed are small, phase II and non-comparative. Combinations studied included nab-paclitaxel plus trastuzumab and/or bevacizumab (with or without additional cytotoxic agents), gemcitabine, capecitabine, carboplatin, or lapatinib. The majority of metastatic and neoadjuvant studies demonstrated satisfactory efficacy and safety for nab-paclitaxel combinations, although conclusions regarding comparison with solvent-based taxane (SBT) regimens are not possible. The two adjuvant studies confirmed the safety of nab-paclitaxel combinations in this setting. CONCLUSIONS: Although results of this review indicate that nab-paclitaxel may be an appropriate substitute for SBTs in combination regimens, additional research is required to confirm the place and cost effectiveness of these combinations before nab-paclitaxel could be recommended routinely in all settings.
    [Abstract] [Full Text] [Related] [New Search]